Personal history of prostate cancer and increased risk of incident melanoma in the United States

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4394-4399

  Li, Wen Qing ^a,b   Qureshi, Abrar A ^b   Ma, Jing ^b   Goldstein, Alisa M ^a   Giovannucci, Edward L ^b,c   Stampfer, Meir J ^b,c   Han, Jiali ^b,d,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; MULTIMODALITY CANCER THERAPY; NONMELANOMA SKIN CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SELF CONCEPT; SELF REPORT; SKIN CANCER; UNITED STATES; WATCHFUL WAITING; ACNE VULGARIS; ARTICLE; COMORBIDITY; HEALTH CARE PERSONNEL; INCIDENCE; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR; STATISTICS; PROCEDURES; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ACNE VULGARIS; ADULT; AGED; COMORBIDITY; FOLLOW-UP STUDIES; HEALTH PERSONNEL; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; UNITED STATES;

EID: 84894304006     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.1915     Document Type: Review

References (33)

1. Travis LB, Demark Wahnefried W, Allan JM, et al: Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10:289-301, 2013
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
3. Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 27:39-66, 2000
4. Nguyen PL, Je Y, Schutz FA, et al: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 306:2359-2366, 2011
5. Hyde Z, Flicker L, McCaul KA, et al: Associations between testosterone levels and incident prostate, lung, and colorectal cancer: A populationbased study. Cancer Epidemiol Biomarkers Prev 21:1319-1329, 2012
6. Gann PH, Hennekens CH, Ma J, et al: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118-1126, 1996 (Pubitemid 26274606)
7. Williams HC, Dellavalle RP, Garner S: Acne vulgaris. Lancet 379:361-372, 2012
8. Sutcliffe S, Giovannucci E, Isaacs WB, et al: Acne and risk of prostate cancer. Int J Cancer 121:2688-2692, 2007 (Pubitemid 350136413)
9. Rampen FH, Mulder JH: Malignant melanoma: An androgen-dependent tumour? Lancet 1:562-564, 1980 (Pubitemid 10155307)
10. Slominski A, Tobin DJ, Shibahara S, et al: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84:1155-1228, 2004 (Pubitemid 39287950)
11. Yang GB, Barnholtz-Sloan JS, Chen Y, et al: Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 147:1395-1402, 2011
12. Braisch U, Meyer M, Radespiel-Tröger M: Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany. Eur J Cancer Prev 21:552-559, 2012
13. Giovannucci E, Rimm EB, Colditz GA, et al: A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571-1579, 1993 (Pubitemid 23304685)
14. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321:129-135, 1989
15. Wilson KM, Kasperzyk JL, Rider JR, et al: Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 103:876-884, 2011
16. Colditz GA, Martin P, Stampfer MJ, et al: Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123:894-900, 1986 (Pubitemid 16049247)
17. Hunter DJ, Colditz GA, Stampfer MJ, et al: Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 2:231-239, 1992
18. van Dam RM, Huang Z, Giovannucci E, et al: Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 71:135-141, 2000 (Pubitemid 30033596)
19. Fears TR, Bird CC, Guerry DT 4th, et al: Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res 62: 3992-3996, 2002 (Pubitemid 34791065)
20. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, et al: Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-183, 2008 (Pubitemid 351480553)
21. Allil PA, Visconti MA, Castrucci AM, et al: Photoperiod and testosterone modulate growth and melanogenesis of s91 murine melanoma. Med Chem 4:100-105, 2008 (Pubitemid 351611799)
22. Hsueh EC, Gupta RK, Lefor A, et al: Androgen blockade enhances response to melanoma vaccine. J Surg Res 110:393-398, 2003 (Pubitemid 36683037)
23. Zhou J, Richardson M, Reddy V, et al: Structural and functional association of androgen receptor with telomeres in prostate cancer cells. Aging (Albany NY) 5:3-17, 2013
24. Kim SH, Richardson M, Chinnakannu K, et al: Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem 285:10472-10476, 2010
25. Calado RT, Yewdell WT, Wilkerson KL, et al: Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 114:2236-2243, 2009
26. Nan H, Du M, De Vivo I, et al: Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 71:6758-6763, 2011
27. Cha E, Fong L: Immunotherapy for prostate cancer: Biology and therapeutic approaches. J Clin Oncol 29:3677-3685, 2011
28. Kwek SS, Cha E, Fong L: Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 12:289-297, 2012
29. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
30. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793-798, 2010
31. Cooper PR, McGuire BB, Helfand BT, et al: Prostate cancer risk alleles and their associations with other malignancies. Urology 78:970.e15-e20, 2011
32. Goldstein AM, Tucker MA: Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 22:528-532, 2013
33. Spanogle JP, Clarke CA, Aroner S, et al: Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol 62:757-767, 2010